Stocks and Investing
Stocks and Investing
Tue, March 7, 2017
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Pantginis Reiterated (TGTX) at Strong Buy and Held Target at $18 on, Mar 7th, 2017
Joseph Pantginis of HC Wainwright & Co., Reiterated "TG Therapeutics, Inc." (TGTX) at Strong Buy and Held Target at $18 on, Mar 7th, 2017.
Joseph has made no other calls on TGTX in the last 4 months.
There is 1 other peer that has a rating on TGTX. Out of the 1 peers that are also analyzing TGTX, 0 agree with Joseph's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joseph
- Jason Wittes of "Aegis Capital" Initiated at Strong Buy and Held Target at $26 on, Wednesday, February 22nd, 2017
Contributing Sources